ACE Inhibitors Are Preferred Over ARBs After STEMI
ACE inhibitors should be the first-line renin-angiotensin system blocker after STEMI, with ARBs reserved only for patients who are intolerant to ACE inhibitors. This recommendation is firmly established in both major international guidelines and supported by contemporary research evidence.
Guideline-Based Recommendations
Both the 2017 ESC Guidelines 1 and 2013 ACCF/AHA Guidelines 2 provide clear hierarchical guidance:
- ACE inhibitors receive Class I, Level A recommendation for patients with STEMI, particularly those with anterior MI, heart failure, or ejection fraction ≤40% 2
- ARBs receive Class I, Level B recommendation only as an alternative for patients with ACE inhibitor intolerance 2
The ACC/AHA guidelines explicitly state that ACE inhibitors are reasonable for ALL patients with STEMI without contraindications (Class IIa, Level A), while ARBs are positioned strictly as second-line therapy 2.
Supporting Research Evidence
Recent high-quality research reinforces ACE inhibitor superiority:
The most compelling evidence comes from a 2019 propensity-matched study of 13,873 STEMI patients who underwent successful PCI with drug-eluting stents 3. After matching 3,296 pairs, the combination of beta-blockers with ARBs showed significantly higher rates of:
- Major adverse cardiac events (8.3% vs 6.8%, HR 1.210, p=0.039)
- All-cause death
- Cardiac death
- Need for revascularization
A parallel 2019 study examining statin combinations found similar results: ARB therapy was associated with significantly higher all-cause mortality (HR 1.548, p=0.014) and cardiac death (HR 1.850, p=0.004) compared to ACE inhibitors 4.
When ARBs Are Appropriate
ARBs should be used in these specific scenarios:
- ACE inhibitor-induced cough (most common reason)
- Angioedema from prior ACE inhibitor exposure
- Other documented ACE inhibitor intolerance
A 2014 Korean registry study demonstrated that when ACE inhibitors cannot be used, ARBs provide comparable efficacy to ACE inhibitors and superior outcomes compared to no renin-angiotensin system blockade 5.
Clinical Implementation Algorithm
- Initiate ACE inhibitor within 24 hours of STEMI presentation unless contraindicated
- Mandatory for: Anterior MI, heart failure, or LVEF ≤40%
- Strongly consider for: All other STEMI patients
- Switch to ARB only if: Patient develops intolerable side effects (cough, angioedema)
- Contraindications to both: Hypotension, cardiogenic shock, bilateral renal artery stenosis, pregnancy, hyperkalemia >5.0 mEq/L, or creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women)
Duration of Therapy
Recent 2026 landmark analysis data suggests the survival benefit is most pronounced in the first 12 months post-STEMI 6. Maintain therapy through this critical period, then reassess based on left ventricular function recovery and individual patient factors.
Important Caveats
- A 2023 meta-analysis of 16 studies found no significant differences between ACE inhibitors and ARBs for MACE, mortality, or stroke 7, but this analysis included heterogeneous populations and older studies from the pre-PCI era
- The mortality benefit of ACE inhibitors over ARBs appears most robust in the contemporary PCI era with drug-eluting stents 3, 4
- Do not combine ACE inhibitors with ARBs - this increases adverse events without additional benefit